Amplia Therapeutics Ltd
ASX:ATX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amplia Therapeutics Ltd
Research & Development
Amplia Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amplia Therapeutics Ltd
ASX:ATX
|
Research & Development
-AU$9.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$60.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Research & Development
-AU$7.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Amplia Therapeutics Ltd
Glance View
Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
See Also
What is Amplia Therapeutics Ltd's Research & Development?
Research & Development
-9.7m
AUD
Based on the financial report for Sep 30, 2025, Amplia Therapeutics Ltd's Research & Development amounts to -9.7m AUD.
What is Amplia Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-45%
Over the last year, the Research & Development growth was -52%. The average annual Research & Development growth rates for Amplia Therapeutics Ltd have been -17% over the past three years , -45% over the past five years .
